Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Role of peroxisome proliferator-activated receptor-gamma in atherosclerosis: an update Wang N; Yin R; Liu Y; Mao G; Xi FCirc J 2011[]; 75 (3): 528-35Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a member of the ligand-activated nuclear receptor family. Thiazolidinediones, such as rosiglitazone and pioglitazone, are synthetic agonists selective for PPARgamma and have been used in the clinical treatment of type 2 diabetes. However, beyond the metabolic effects on glycemic control, PPARgamma and its ligands also have profound effects on cardiovascular biological and pathophysiological processes. As cardiovascular diseases are closely associated with insulin resistance, and the major cause of death and complications of type 2 diabetes, a comprehensive understanding of the cardiovascular roles of this receptor is critical for the rational application of the existing agonists and the future development of therapeutic modulators. Therefore, this review will focus on the recent advances regarding the cardiovascular functions of PPARgamma and its recognized effects on major cardiovascular diseases, in particular, atherosclerosis and associated processes.|Animals[MESH]|Atherosclerosis/*physiopathology[MESH]|Cardiovascular System/physiopathology[MESH]|Disease Models, Animal[MESH]|Humans[MESH]|Inflammation/physiopathology[MESH]|Lipid Metabolism/physiology[MESH]|PPAR gamma/*physiology[MESH] |